Michael Barbella, Managing Editor02.21.23
Due to its aging population, Japan is experiencing a sharp increase in neurological disorders such as Alzheimer's disease (AD). Consequently, new in-vitro diagnostics (IVD) and high-precision imaging modalities are being developed to meet the growing need for better neurological healthcare. These innovative solutions will not only facilitate the future expansion of the medical device industry but also enable better care for patients with neurological disorders, claims GlobalData.
Hamamatsu Photonics KK and Hamamatsu Medical Photonics Foundation's 'HIAS-29000' positron emission tomography (PET) scanner has recently obtained the Pharmaceuticals and Medical Devices Agency clearance as a medical device. The motion correction feature of the HIAS-29000 scanner corrects blurry images for scans associated with patients who cannot maintain a stable posture during PET scans.
“AD appears to be the underlying cause of more than 60% of dementia cases. Therefore, PET scanners with motion correction features will increase diagnostic precision for dementia and psychiatric disorders. The additional information garnered from these image analyses will support the development of innovative drugs,” said Dr. Satyajeet Salunkhe, a medical devices analyst at GlobalData.
Recently, Shimadzu Corp., Eisai Co. Ltd., and academic partners Oita University and Usuki City Medical Association have collaborated to create a blood biomarker-based methodology for early AD identification.
“Amyloid beta, the protein thought to cause AD, begins to build up in the brain about 20 years before symptoms appear. Biomarker-based identification will facilitate early identification of AD and better planning of the healthcare for patients,” Dr. Salunkhe explained.
GlobalData’s research indicates that Japan holds a strong position in the diagnostic imaging market, with approximately 26.9% share in the Asia-Pacific region. Novel solutions such as PET scanners with motion correction will expedite the growth of the nuclear imaging equipment market in Japan. By contrast, active industry-academia cooperation in Japan will facilitate the development of new IVD tests that will catalyze the growth in the IVD analyzers and reagents market.
“Early detection is a key prognostic factor in neurological disorders. Blood-based diagnostic tests will not only be less expensive than other invasive procedures but also will help in the early diagnosis of neurological disorders. Affordable testing will make these diagnostic procedures accessible to people of all socioeconomic backgrounds and ensure equitable access to healthcare for all,” Dr. Salunkhe concluded.
Hamamatsu Photonics KK and Hamamatsu Medical Photonics Foundation's 'HIAS-29000' positron emission tomography (PET) scanner has recently obtained the Pharmaceuticals and Medical Devices Agency clearance as a medical device. The motion correction feature of the HIAS-29000 scanner corrects blurry images for scans associated with patients who cannot maintain a stable posture during PET scans.
“AD appears to be the underlying cause of more than 60% of dementia cases. Therefore, PET scanners with motion correction features will increase diagnostic precision for dementia and psychiatric disorders. The additional information garnered from these image analyses will support the development of innovative drugs,” said Dr. Satyajeet Salunkhe, a medical devices analyst at GlobalData.
Recently, Shimadzu Corp., Eisai Co. Ltd., and academic partners Oita University and Usuki City Medical Association have collaborated to create a blood biomarker-based methodology for early AD identification.
“Amyloid beta, the protein thought to cause AD, begins to build up in the brain about 20 years before symptoms appear. Biomarker-based identification will facilitate early identification of AD and better planning of the healthcare for patients,” Dr. Salunkhe explained.
GlobalData’s research indicates that Japan holds a strong position in the diagnostic imaging market, with approximately 26.9% share in the Asia-Pacific region. Novel solutions such as PET scanners with motion correction will expedite the growth of the nuclear imaging equipment market in Japan. By contrast, active industry-academia cooperation in Japan will facilitate the development of new IVD tests that will catalyze the growth in the IVD analyzers and reagents market.
“Early detection is a key prognostic factor in neurological disorders. Blood-based diagnostic tests will not only be less expensive than other invasive procedures but also will help in the early diagnosis of neurological disorders. Affordable testing will make these diagnostic procedures accessible to people of all socioeconomic backgrounds and ensure equitable access to healthcare for all,” Dr. Salunkhe concluded.